Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Feb;10(2):597-599.
doi: 10.21037/jtd.2017.12.136.

The reality of complexity: concomitant genomic alterations in patients with EGFR mutations

Andrés F Cardona  1   2   3 , Zyanya Lucia Zatarain-Barrón  4 , Leonardo Rojas  1   2   5 , Oscar Arrieta  4
Affiliations
Editorial

The reality of complexity: concomitant genomic alterations in patients with EGFR mutations

Andrés F Cardona et al. J Thorac Dis. 2018 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

  • Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
    Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Blakely CM, et al. Nat Genet. 2017 Dec;49(12):1693-1704. doi: 10.1038/ng.3990. Epub 2017 Nov 6. Nat Genet. 2017. PMID: 29106415 Free PMC article.

References

    1. Arrieta O, Guzmán-de Alba E, Alba-López LF, et al. National consensus of diagnosis and treatment of non-small cell lung cancer. Rev Invest Clin 2013;65 Suppl 1:S5-84. - PubMed
    1. Arrieta O, Cardona AF, Corrales L, et al. The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer. Lung Cancer 2015;87:169-75. 10.1016/j.lungcan.2014.12.009 - DOI - PubMed
    1. Molina-Vila MA, Bertran-Alamillo J, Gascó A, et al. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res 2014;20:4647-59. 10.1158/1078-0432.CCR-13-2391 - DOI - PubMed
    1. Canale M, Petracci E, Delmonte A, et al. Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clin Cancer Res 2017;23:2195-202. 10.1158/1078-0432.CCR-16-0966 - DOI - PubMed
    1. VanderLaan PA, Rangachari D, Mockus SM, et al. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer 2017;106:17-21. 10.1016/j.lungcan.2017.01.011 - DOI - PMC - PubMed